SynthesisFrontiers in microbiology2026
Fecal microbiota transplantation in obesity: a comprehensive overview from basic research to clinical application.
Synthesis in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity involves microbiota dysbiosis, low-grade inflammation, and insulin resistance, which interacts with multiple metabolic disorders. Fecal microbiota transplantation (FMT) is an emerging therapeutic approach in obesity that enhances intestinal barrier function and regulates energy metabolism. Aim: To provide a comprehensive overview of publication trends, research collaborations, hotspots, future directions, and the current clinical application status of FMT in obesity. Methods: Literature searches were conducted in the Web of Science (WoS) and PubMed databases. The primary analysis was performed using the WoS database for bibliometric analysis, while PubMed was searched to supplement the clinical research landscape, ensuring data comprehensiveness and methodological rigor. Results: A total of 517 papers were finally included, of which 116 (22.44%) were published in the top 10 academic journals. Most publications originated from China ( Conclusion: Although FMT shows promise, its clinical benefits remain transient and variable across individuals. Current evidence does not yet support routine clinical application. Targeted oral microbiota supplementation may represent a future direction, but high-quality, large-scale clinical trials are urgently needed to establish standardized protocols and evaluate long-term safety and efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.